Combining the monoclonal antibody atezolizumab with a carboplatin-paclitaxel chemotherapy regimen and the biologic antiangiogenic agent bevacizumab led to a significant progression-free survival (PFS) benefit in chemotherapy-naïve patients with non-squamous metastatic non-small-cell lung cancer (mNSCLC), according to the IMpower150* trial presented at ELCC 2018.
Low baseline levels of the biomarker endoglin may signal improved progression-free survival (PFS) and/or overall survival (OS) in chemotherapy-naïve patients with unresectable epithelioid malignant pleural mesothelioma (MPM) who received the triple angiokinase inhibitor nintedanib in addition to a doublet combination regimen comprising pemetrexed and cisplatin, according to results from the LUME Meso* trial presented at ELCC 2018.
Even in the long term, atezolizumab shows significant survival benefit over docetaxel for patients with advanced non-small–cell lung cancer (NSCLC) who have previously been treated, regardless of PD-L1 expression levels or tumour histology, according to the POPLAR* study presented at the 2018 European Lung Cancer Congress (ELCC).
First-generation EGFR tyrosine kinase inhibitor (TKI) therapy is less effective in patients with advanced lung adenocarcinoma who have complex EGFR mutations and primary drug-resistance patterns, according to results of a Chinese study reported at ELCC 2018.
The next-generation TKI* alectinib maintains improvement in lung cancer symptoms for a longer duration than crizotinib, the current standard of care for patients with ALK-positive non-small–cell lung cancer (NSCLC), according to new data from the ALEX** study presented at ELCC 2018.
The first-line use of osimertinib in patients with EGFR mutation–positive advanced non-small-cell lung cancer (NSCLC) is associated with significant improvements in a number of post-progression endpoints compared with current standard of care (SoC), according to new data from the phase III FLAURA study.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Dr. Jay Zhu, Dr. Lai Fung Li, Prof. Chae-Yong Kim,
27 Nov 2019
The current standard
of care for glioblastoma multiforme (GBM), an aggressive primary brain tumour
with a rapid disease course, consists of maximum safe surgical resection
followed by radiotherapy with concomitant temozolomide (TMZ) chemotherapy and
subsequent TMZ maintenance. At the 16th Annual Meeting of the Asian
Society of Neuro-Oncology (ASNO) in Taipei, Taiwan, experts reviewed the
evidence and shared their clinical experience on the use of tumour treating
fields (TTFields), a novel treatment modality for GBM.
There appears to be no significant survival difference between first-line immune checkpoint inhibitor (ICI) and carboplatin-based chemotherapy in cisplatin-ineligible metastatic urothelial carcinoma patients, according to a Taiwan study presented at the recent 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).